Navigation Links
Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation
Date:2/23/2011

s disease, but these data are extremely exciting, especially for people with the G551D mutation and their families. The results also offer significant hope that a similar approach to treatment may help the majority of patients living with CF."

The Phase 3 data support Vertex's plan to submit a New Drug Application for VX-770 to the U.S. Food and Drug Administration (FDA) in the second half of 2011. Generally, the FDA takes between 6 and 12 months to review and rule on a drug application.

"The Cystic Fibrosis Foundation has played an instrumental role in our more than 10-year effort to discover and develop potential new CF medicines such as VX-770," said Matthew W. Emmens, chairman, president and CEO of Vertex. "The data announced today reflect a significant investment of time, dollars and scientific expertise from both Vertex and the CF Foundation, and we look forward to working closely with the Foundation as we seek to bring VX-770 to people with CF."

Said Preston W. Campbell III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation: "As a physician who has treated CF patients for many years, the VX-770 results are more than just numbers -- they represent hope." He added, "It's not surprising that patients felt better on the drug because of the magnitude of lung function improvement and weight gain. These are important clinical outcomes, and the fact they were maintained through 48 weeks is very encouraging."

Developing a therapy for individuals with the most common CF mutation, Delta F508, remains a top priority of the CF Foundation. A Phase 2 trial for those with Delta F508 is underway to test VX-770 in combination with a drug known as VX-809. Like VX-770, VX-809 resulted from discovery efforts between Vertex and the CF Foundation. Laboratory studies suggest a combination of the two drugs may be more beneficial than either one alone. Results of this clinical trial are expected later this year.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Acsis Inc., the market ... solutions, announced it will be hosting a free webinar ... event, "How to Boost Manufacturing Efficiency and Optimize Supply ... at 2:00 PM EDT.  Presenters ... John Gordon , Chief Information Officer for Roosevelt ...
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)... March 4, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of innovative ... will present at the Barclays Global Healthcare Conference ... Loews Miami Beach Hotel in Miami ... , M.D., President and Chief Executive Officer of Aratana ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2
...  1, 2011 CardioGenics Holdings Inc. (OTC Bulletin ... CardioGenics and Merck Chimie SAS continue the commercialization ... CardioGenics that while it is refining its encapsulation ... a batch of magnetic beads coated with CardioGenics, ...
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
Cached Medicine Technology:CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 2CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS 3Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
(Date:3/4/2015)... 2015 " Optrix by Body Glove ... monthly Tech Report, which takes a look at the ... consumers. Scott Steinberg, a special reporter for NewsWatch and ... with viewers how they have an ultra-rugged, waterproof case ... is a major player at the Consumer Electronics Show ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 The ... launch of their new L-Style Revolution™ Program. The customized ... men and women of all health and fitness levels ... maintenance goals faster than traditional methods. , “We’re really ... available customized plans based on award winning techniques to ...
(Date:3/4/2015)... VA (PRWEB) March 04, 2015 ... that John Dvorak has joined the company ... for charting the technology focus for the company, including ... Mr. Dvorak brings 20 years of experience as a ... served in diverse roles at the FBI including oversight ...
(Date:3/4/2015)... 2015 In a small ceremony with 20 ... their new facility in New Port Richey on February 24, ... facility will allow the Florida drug detox facility ... abuse epidemic through treatment and education. “Due to our unique ... the United States, we made the decision that expanding our ...
(Date:3/4/2015)... 2015 i2i Systems Population Health ... Chase Brexton Health Care, a 35-year-old Maryland-based community ... Brexton provides comprehensive primary care, behavioral health and ... seven clinics in the greater Baltimore area of ... records, the organization has always focused on providing ...
Breaking Medicine News(10 mins):Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3
... to invest Rs.60 billion to upgrade its rundown medical colleges ... the challenge from the state's flourishing private healthcare industry.// ... three medical colleges in Assam would give the private nursing ... Health Minister Himanta Biswa Sarma told IANS. ,The ...
... called Six2 plays a critical role in the development ... stem cells constantly available to produce the differentiated cells ... //according to investigators at St. Jude Children's Research Hospital. ... cell develops characteristics specific to its job in the ...
... countrywide study, antipsychotic drugs that are prescribed for delusions, ... disease as most of the patients discontinue the drugs ... was conducted by Lon Schneider, professor of psychiatry, neurology ... of Medicine of the University of Southern California (USC). ...
... see their doctors for answers, but when it comes ... detect the earliest cancers. While certain tests can indicate ... simple office-based test to monitor patients for cancer currently ... ,Researchers at the University of Virginia School of Medicine ...
... in some way. For some people, the most convenient ... in exercise machines to help burn calories and increase ... preferences, budget and health, some aerobic exercise machines may ... of Mayo Clinic Health Letter covers some options: ...
... of Agriculture's (USDA) Food Safety and Inspection Service (FSIS) ... //that a consignment of pork products that were manufactured ... establishments in the state of Ohio , and ... monocytogenes This was established through microbiological testing. ,Following ...
Cached Medicine News:Health News:Assam Government to Invest Rs. 60 bn to Improve Healthcare Industry 2Health News:Key Gene Controlling Kidney Development Found 2Health News:Researchers Developing Office-Based Cancer Screening Test 2Health News:Home Is Where the Gym Is 2
... first fully automated blood ... North American market based ... Test™. The ORTHO ProVue™ ... while increasing productivity via ...
... people are in need of MRI exams, ... tunnel-type scanners. They have heard of, or ... claustrophobic and noisy tubes of supercon scanners ... What people want is a patient-friendly MRI. ...
Thesystem combines an exclusive dual light-source design and a versatile sample compartment to provide solid, reliable performance....
... The Gemini XPS ... high-sensitivity measurements as required ... fluorescence-based assays. Cellular and ... quantitation, drug screening, and ...
Medicine Products: